Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Stellar highlights Q2 network progress and outlines 2025 roadmap in leadership webinar

Stellar highlights Q2 network progress and outlines 2025 roadmap in leadership webinar

CointurkCointurk2026/07/31 13:18
By:Cointurk

The Stellar Development Foundation (SDF) hosted a live webinar at 3pm ET, bringing together senior executives to review recent network performance and share expectations for the second half of 2025. The session featured CEO Denelle Dixon, Chief Product Officer Tomer Weller, Chief Technology Officer Raja Chakraborty, and VP of Product Jose Da Ponte.

Q2 network growth and product advancements

The leadership team reported steady progress throughout the second quarter, emphasizing the expansion of payment volumes, advances in tokenization, and upgrades to developer tools. Stellar, which operates as an open blockchain focused on fast, low-cost global payments, continues to attract real-world asset issuers and stablecoin projects.

While the SDF did not disclose specific growth metrics for Q2, it identified an uptick in active accounts and newly issued assets as primary indicators of institutional and fintech adoption on the Stellar network.

Stellar has concentrated on growing network participation by making tokenization and payment solutions more accessible to businesses and developers integrating real-world assets and regulated digital currencies.

Leadership insights and ecosystem priorities

Panelists including Dixon, Da Ponte, Weller, and Chakraborty outlined the current strategy that links new protocol features to practical business applications. The team discussed ongoing integration of Soroban smart contracts and regulatory compliance tools, which are increasingly in demand among companies seeking to launch regulated assets and streamline digital operations.

In addition to improving underlying infrastructure, the SDF plans to develop user-friendly products tailored to crypto exchanges, custodians, and legacy financial institutions. This approach aims to facilitate compliance with dynamic global regulations, positioning Stellar as a viable settlement network for institutional clients.

The Foundation also mentioned product priorities for the months ahead, focusing on real-world asset tokenization, cross-border payments, and new incentive programs for its ecosystem. These initiatives come as part of a broader industry trend, with increased institutional interest in blockchain-based settlements and asset digitization—an area also being advanced by platforms such as Ethereum and Polygon.

Mini dictionary: Soroban is a smart contract platform built for Stellar that enables developers to deploy decentralized applications with support for advanced logic and programmable features. Designed for scale, Soroban allows for the customization of on-chain assets and supports compliance with regulatory requirements.

By focusing on regulatory-compliant infrastructure and ecosystem incentives, Stellar intends to accelerate network usage and adoption among established financial players entering the digital asset sector.

Network Main Focus Q2 Developments
Stellar Payments, RWA tokenization Active accounts and asset issuance up; new smart contract tools (Soroban)
Ethereum Smart contracts, DeFi Institutional settlement platforms, ongoing scaling upgrades
Polygon Scalability, sidechains Rising settlement volumes, expanded business partnerships
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Phase III trial failure for new heart drug causes Novo Nordisk shares to plunge: increasing reliance on weight-loss drugs, R&D transformation faces new test

Novo Nordisk announced on Friday that its cardiovascular drug ziltivekimab failed to reduce the risk of major cardiovascular events in a phase III clinical trial involving 6,300 patients, causing its stock price to plummet by 8.7% in a single day. The market had held high expectations for ziltivekimab, hoping the drug would establish a second growth curve beyond diabetes and weight-loss medications.

华尔街见闻2026/07/31 22:26